Alps Advisors Inc. Has $32.19 Million Position in Johnson & Johnson (JNJ)

Alps Advisors Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1,661.6% in the second quarter, Holdings Channel reports. The fund owned 265,292 shares of the company’s stock after purchasing an additional 250,232 shares during the quarter. Alps Advisors Inc.’s holdings in Johnson & Johnson were worth $32,191,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of JNJ. BlackRock Inc. lifted its position in Johnson & Johnson by 4.7% during the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after acquiring an additional 7,853,141 shares during the last quarter. Cornerstone Wealth Management LLC lifted its position in Johnson & Johnson by 10,307.6% during the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after acquiring an additional 2,473,105 shares during the last quarter. Bank of Montreal Can lifted its position in Johnson & Johnson by 36.1% during the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after acquiring an additional 1,833,622 shares during the last quarter. Summit Trail Advisors LLC lifted its position in Johnson & Johnson by 11,692.6% during the first quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after acquiring an additional 1,752,841 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its position in Johnson & Johnson by 212.7% during the second quarter. Public Employees Retirement Association of Colorado now owns 1,498,023 shares of the company’s stock valued at $181,770,000 after acquiring an additional 1,019,002 shares during the last quarter. 66.06% of the stock is owned by institutional investors.

NYSE JNJ opened at $141.99 on Friday. The firm has a market capitalization of $392.91 billion, a price-to-earnings ratio of 19.45, a P/E/G ratio of 2.29 and a beta of 0.58. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.75. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The firm had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same quarter last year, the company posted $1.90 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. As a group, equities analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

In related news, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Alex Gorsky sold 264,465 shares of the firm’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the transaction, the chief executive officer now directly owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 349,805 shares of company stock valued at $50,593,707. 0.22% of the stock is currently owned by corporate insiders.

A number of research analysts have issued reports on JNJ shares. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Tuesday. Citigroup raised their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a report on Monday, October 22nd. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. Raymond James raised their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $143.97.

COPYRIGHT VIOLATION WARNING: This story was first reported by WKRB News and is the property of of WKRB News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.wkrb13.com/2018/11/23/alps-advisors-inc-has-32-19-million-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply